PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629330
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629330
Renal Denervation Devices Market size was valued at US$ 251.09 Million in 2024, expanding at a CAGR of 40.98% from 2025 to 2032.
A minimally invasive technique called renal denervation attempts to reduce the sympathetic nervous system's activity in the kidneys. A catheter is inserted via the arteries and into the renal arteries, which provide blood to the kidneys. The gadget then sends electricity to the vessel wall's nerves to interfere with the signals that can lead to hypertension. There are several ways to provide the energy, including radiofrequency ablation, ultrasound, and, more recently, chemical injections directly or novel techniques based on percutaneous delivery systems. The growing prevalence of hypertension is one of several factors driving the market's expansion. Furthermore, during the projected period, the renal denervation devices market is anticipated to rise as a result of the growing acceptance of innovative goods. For instance, the medical device business Kalos Medical was awarded Won4.67m (about $3.5m) to develop further their renal denervation medical device for the treatment of hypertension. Technological advancements in renal denervation (RDN) products, the growing elderly population, the short-term and permanent effects of renal denervation procedures, and the rising incidence of uncontrolled and treatment-resistant or drug-resistant hypertension (trHTN) are additional factors propelling the renal denervation devices market growth.
Renal Denervation Devices Market- Market Dynamics
Rising Prevalence of Hypertension
The market for renal denervation devices is anticipated to develop in the future due to the rising prevalence of hypertension. When the force of blood flowing through the blood arteries is continuously too high, it is referred to as hypertension or high blood pressure. For patients with resistant hypertension, renal denervation-a catheter-based procedure-has become a viable treatment option. A minimally invasive, experimental treatment for hypertension that has not improved with medicines is renal denervation. For instance, in January 2023, the Mississippi State Department of Health, a Mississippi state health department situated in the United States, reported that approximately 1 million adult Mississippians (43.9%) had high blood pressure in 2021. The prevalence of hypertension was 36.3% greater in MS in 2021 than in the US (MS: 43.9%, US: 32.2%). Thus, the market for renal denervation devices will expand as a result of the rising incidence of hypertension.
Renal Denervation Devices Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 40.98% over the forecast period (2025-2032)
Based on technology segmentation, radio frequency ablation was predicted to show maximum market share in the year 2024
Based on end-user segmentation, hospitals were the leading segment in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Renal Denervation Devices Market is segmented on the basis of Technology, Product, End-user, and Region.
On the basis of technology, the market is segregated into Radio Frequency Ablation, Brachytherapy, Ultrasound Energy-based RDN, Chemical Ablation, and Others. In 2024, the market was dominated by the radio frequency ablation category because of its established market presence and the large number of successful surgeries carried out using this technology. This technique, which has been widely used since its inception, uses radiofrequency energy to break up hyperactive renal nerves. For instance, Kauvery Hospital in India introduced a novel renal denervation treatment based on radiofrequency for persistent hypertension in May 2024. The Indian government-approved technique demonstrated promising outcomes in lowering nerve activity and treating severe, drug-resistant hypertension, highlighting the technology's market leadership.
Based on end-user, the market is divided into Hospitals, Clinics, Cardiovascular research centre, and Others. In 2024, the hospitals category held a dominant market share because of their sophisticated infrastructure, highly skilled personnel, and resources for intricate processes. Due to well-established reimbursement structures and supportive healthcare policies that make it easier for patients to receive state-of-the-art therapies, these facilities are very successful at handling cases of resistant hypertension. Hospitals are essential for clinical trials that assess the safety and effectiveness of novel renal denervation therapies, in addition to their core duties. The field is advanced by this research, which also aids in the early integration of novel tools and methods into standard medical practice. These institutes enhance treatment regimens for hypertension patients by actively engaging in trials and helping to develop evidence-based procedures.
Renal Denervation Devices Market- Geographical Insights
In 2024, North America led the renal denervation devices industry, mostly due to significant technological advancements and a high amount of FDA approval requests. In 2023, the FDA authorized the "Symplicity Spyral System and Ultrasound-based Paradise Device" as one of two renal denervation devices in the US. Furthermore, the region's dominance is attributed to a number of factors, including an ageing population, changing lifestyles, and the high prevalence of hypertension. The market's growth is also primarily driven by increasing R&D efforts to produce efficient devices. The rise in local new launches is another aspect propelling the renal denervation devices market's growth.
The market for renal denervation devices is anticipated to develop significantly in Europe due to factors like the procedure's long-lasting effects, rising rates of hypertension, and increased technological advancements. For instance, according to data from the Office of Health Improvement and Disparities, 8,457,600 people in England had hypertension in 2021. Furthermore, 73.6% of respondents to a survey done in Italy in 2021 said they were aware of their blood pressure, 42.3% said they had been diagnosed with hypertension, and 41.4% said they were taking antihypertensive drugs. Additionally, men were more likely than women to self-report having hypertension. Consequently, one of the main causes of the region's expansion is the rising prevalence of hypertension.
The fierce rivalry between different industry participants is a defining feature of the competitive environment of the worldwide renal denervation devices market. Large industry participants are aggressively pursuing a number of tactics to bolster their worldwide footprint, including Medtronic PLC, ReCor Medical Inc. (Otsuka Holdings Co. Ltd), St. Jude Medical Inc. (Abbott Laboratories), Symple Surgical Inc., Ablative Solutions Inc., Covidien PLC, Mercator MedSystems Inc., and others. Furthermore, numerous medical device makers, research institutes, and healthcare providers are participating in the market in an effort to provide novel technologies and treatment strategies for renal denervation devices. Through partnerships, collaborations, and research and development initiatives, these players are committed to furthering the area. Additionally, product innovation is a major trend that is becoming more and more popular in the market for renal denervation devices. Large firms in the market for renal denervation devices are concentrating on creating cutting-edge goods to improve their standing and obtain a competitive edge. For instance, ReCor Medical Inc., a US-based manufacturer of medical devices, introduced the Paradise Ultrasound Renal Denervation System in October 2021 to treat hypertension. Using non-focused ultrasound, this technique treats hyperactive nerves that go to the kidney in a less invasive manner. When compared to a sham operation, the Paradise System has been demonstrated to lower blood pressure successfully.
Recent Development
June 2024: DeepQure Inc., a medical device business based in Seoul, South Korea, stated that it has approved an experimental device exemption from the FDA and is now beginning an early feasibility study (EFS) for the HyperQure renal denervation (RDN) system. For the treatment of resistant hypertension, RDN uses the extravascular laparoscopic tool HyperQure.
April 2024: The FDA has approved the paradise ultrasound renal denervation system, according to a statement released by Recor Medical, Inc. and its parent firm, Otsuka Medical Devices Co., Ltd. This cutting-edge technology, which is currently on the market, was recently introduced to the Middle Eastern market at Al Qassimi Hospital in Sharjah, United Arab Emirates. The Paradise system offers a revolutionary approach to treating resistant hypertension by using cutting-edge ultrasound technology to target and interrupt hyperactive renal neurons.
November 2023: The US-based medical equipment business Recor Medical introduced Paradise Ultrasound Renal Denervation Therapy. The sympathetic nerves around the renal arteries are denervated utilizing ultrasound technology, which is the first FDA-approved renal denervation therapy in the US. This reduces the overactivity that can cause hypertension. As a much-needed breakthrough in the management of hypertension, the Paradise System has demonstrated notable drops in blood pressure in clinical testing.